This Nu Holdings Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Wednesday
Analysts downgraded NU, BAK, CLLS and CBZ; price targets for NU, BAK and CLLS were cut sharply.
Stocks · News reference
Cellectis shares are trading lower after Barclays downgraded the stock from Overweight to Underweight rating and lowered its price target from $9 to $1.3.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday
Analysts raised targets for RAPP, ALLR, UNP and ALVO; cut targets for NU, CLLS and JBHT, with several rating upgrades and downgrades.
Barclays Downgrades Cellectis to Underweight, Lowers Price Target to $1.3
Barclays analyst Lukas Shumway downgrades Cellectis (NASDAQ:CLLS) from Overweight to Underweight and lowers the price target from $9 to $1.3.